AROMATASE INHIBITORS
COMPARED
Letrozole, anastrozole, and exemestane all block oestrogen production in post-menopausal women — but they differ in chemical class, specific metabolic effects, and the side-effect profiles that determine which agent a patient can tolerate for 5–10 years.
analyticsAt a Glance
- check_circleAll three AIs reduce oestrogen levels by >95% and are superior to tamoxifen for post-menopausal ER+ breast cancer
- check_circleLetrozole and anastrozole are non-steroidal; exemestane is steroidal — this drives their different side-effect profiles
- check_circleArthralgia (joint pain) affects 40–50% of AI users — switching between AIs resolves symptoms in 50–60% of cases
- check_circleBone density loss requires DEXA monitoring, calcium/vitamin D supplementation, and bisphosphonates if T-score falls below –2.0
How Aromatase Inhibitors Work — and Why They Are Superior to Tamoxifen in Post-Menopausal Women
After menopause, the ovaries stop producing oestrogen — but oestrogen production does not stop entirely. The enzyme aromatase (CYP19A1) converts androgens (primarily androstenedione and testosterone) to oestrogen in peripheral tissues — fat, muscle, liver, and the breast tumour itself. Aromatase inhibitors block this enzyme, reducing oestrogen to near-undetectable levels in post-menopausal women.
“Aromatase inhibitors are not effective in premenopausal women because the ovaries produce oestrogen through a completely different pathway — the aromatase enzyme only accounts for peripheral conversion, not ovarian synthesis. In premenopausal women, ovarian suppression must accompany AI to make this treatment work.”
Why AIs Outperform Tamoxifen in Post-Menopausal Women
Tamoxifen blocks the oestrogen receptor but does not eliminate oestrogen — meaning residual oestrogen can still stimulate other signalling pathways. AIs eliminate the oestrogen stimulus entirely. The ATAC, BIG 1-98, and TEAM randomised trials all showed AIs reduce recurrence risk more effectively than tamoxifen in post-menopausal women — with relative risk reductions of 15–25% in favour of AIs.
Non-Steroidal vs Steroidal: The Chemical Divide
Letrozole and anastrozole are non-steroidal triazole compounds — they reversibly bind and block aromatase. Exemestane is a steroidal compound structurally similar to androstenedione — it irreversibly inactivates aromatase ('suicide inhibition'). This structural difference explains some of the different side-effect profiles: exemestane's androgen-like structure may contribute to different effects on bone, cholesterol, and libido than the non-steroidal agents.
Letrozole vs Anastrozole vs Exemestane: Head-to-Head Comparison
A structured comparison of the three AIs across the parameters that most influence clinical and patient decision-making.
| Parameter | Letrozole (Femara) | Anastrozole (Arimidex) | Exemestane (Aromasin) |
|---|---|---|---|
| Chemical class | Non-steroidal triazole | Non-steroidal triazole | Steroidal (androstane derivative) |
| Mechanism | Reversible aromatase inhibition | Reversible aromatase inhibition | Irreversible aromatase inactivation |
| Oestrogen suppression | >98–99% | >97–99% | >95–98% |
| Standard dose | 2.5 mg daily | 1 mg daily | 25 mg daily |
| Adjuvant evidence | BIG 1-98 trial (DFS superior to tamoxifen) | ATAC trial (DFS superior to tamoxifen) | TEAM trial (non-inferior to tamoxifen → anastrozole) |
| Arthralgia risk | Moderate (40–50%) | Moderate (40–50%) | Possibly lower — androgen-like structure may protect |
| Bone loss | Significant — DEXA required | Significant — DEXA required | Less bone loss than non-steroidal AIs in some studies; weak androgenic effect may be protective |
| Cholesterol effects | Increases LDL; use with caution in dyslipidaemia | Similar to letrozole — LDL increase | May improve lipid profile slightly vs non-steroidal AIs |
| Vaginal dryness/atrophy | Common — similar to other AIs | Common | Common |
| CYP2D6 interaction | None — no interaction with SSRIs | None | None |
| When preferred | High-risk adjuvant; metastatic first-line | Post-DCIS; adjuvant if equivalently tolerated | Switching option after non-steroidal AI intolerance |
Aromatase Inhibitors vs Tamoxifen: Landmark Trial Results
The three major randomised trials established AI superiority over tamoxifen in post-menopausal ER+ breast cancer.
ATAC Trial: Anastrozole vs Tamoxifen — Disease-Free Survival (10-Year Update)
Source: Forbes JF et al., Lancet Oncol 2008; 5-year treatment with 10-year follow-up; ER-positive subgroup
- 10-year DFS: Anastrozole72%
- 10-year DFS: Tamoxifen68%
- Breast cancer recurrence reduction (HR 0.73)27%
BIG 1-98 Trial: Letrozole vs Tamoxifen — Disease-Free Survival
Source: Regan MM et al., NEJM 2011; ER-positive post-menopausal; 8-year median follow-up
- 8-year DFS: Letrozole73.9%
- 8-year DFS: Tamoxifen70.7%
- OS benefit (HR 0.79)21% relative reduction
Managing AI Side Effects: Evidence-Based Strategies
The most common reasons for AI discontinuation are arthralgia and bone loss — both of which are manageable with specific interventions.
| Side Effect | Frequency | Evidence-Based Management | When to Switch Agent |
|---|---|---|---|
| Arthralgia / joint stiffness | 40–50% | Exercise (RCT evidence); acupuncture (SWOG S0927); duloxetine 30–60 mg; switch to a different AI | If significantly limiting function after 3-month trial of management strategies |
| Bone density loss | Accelerated vs tamoxifen | Calcium 1000–1200 mg/day + vitamin D 800–1000 IU; DEXA at baseline and 2 years; zoledronic acid or denosumab if T-score < –2.0 | If bone loss is severe — switching to exemestane may offer marginal bone advantage |
| Hot flushes | Up to 70% | Venlafaxine 75 mg (most evidence); gabapentin 300 mg TDS; oxybutynin; clonidine; lifestyle measures | Hot flushes alone rarely warrant AI switch — pharmacological management preferred |
| Vaginal dryness / atrophy | 50–60% | Non-hormonal lubricants (Replens, YES); local vaginal oestrogen (low-dose — discuss with oncologist) | AI switch not indicated for vaginal symptoms alone; topical oestrogen is usually safe |
| Fatigue | 30–40% | Graded exercise; optimise sleep; screen for anaemia, thyroid dysfunction, and depression | If fatigue is attributed to AI and not other causes — discuss switching or dose holiday |
| Cognitive effects ('chemo-brain') | 15–20% | Exercise; cognitive rehabilitation; screen for depression and sleep disorders | Rarely isolated cause — multifactorial assessment first |
When and How to Switch Between Aromatase Inhibitors
Switching from one AI to another resolves arthralgia in 50–60% of patients — a simple strategy that prevents unnecessary early discontinuation.
- 1
Confirm the Side Effect Is AI-Related
Arthralgia, myalgia, and joint stiffness should be differentiated from other causes — pre-existing osteoarthritis, inflammatory arthritis, vitamin D deficiency, or hypothyroidism can all present similarly. Blood tests (TSH, ESR, CRP, vitamin D, CK) and rheumatology review if needed before attributing symptoms definitively to the AI.
- 2
Trial of Management Strategies
Before switching the AI, a 4–8 week trial of graded aerobic exercise, NSAIDs, and omega-3 supplementation should be attempted. Vitamin D repletion to >75 nmol/L is important as deficiency exacerbates AI arthralgia.
- 3
Switch to a Different AI
If arthralgia persists despite management: switch from a non-steroidal AI (letrozole or anastrozole) to exemestane, or between letrozole and anastrozole. Exemestane resolves non-steroidal AI arthralgia in approximately 50–60% of patients — likely because its steroidal structure has a different interaction with joint tissues.
- 4
If All AIs Are Intolerable
If all three AIs cause intolerable side effects after systematic switching: tamoxifen remains an effective alternative in post-menopausal women — less effective than an AI, but substantially better than no endocrine therapy. Fulvestrant is another option for post-menopausal women in the adjuvant or metastatic setting.
- 5
Document the Switch
Ensure the AI switch is clearly documented in the oncology record with the reason — so that future oncologists, prescribers, and pharmacists understand the history and do not inadvertently prescribe a previously intolerable agent.
More from the Hormone Therapy Resource Library
Continue exploring endocrine therapy — from receptor status and tamoxifen to ovarian suppression and CDK4/6 inhibitors.
- What Is Hormone Therapy for Cancer and How Does It Work?
- ER, PR, and HER2 Status Explained: What the Results Mean
- Tamoxifen: Side Effects, CYP2D6 Interactions, and Monitoring
- Ovarian Suppression for Breast Cancer: Goserelin and Oophorectomy
- Hormone Therapy for Breast Cancer — Complete Guide
- CDK4/6 Inhibitors in Breast Cancer
Frequently Asked Questions
Common questions from patients taking aromatase inhibitors.
About Aromatase Inhibitors
I am premenopausal — can I take an aromatase inhibitor?
Aromatase inhibitors alone are not effective in premenopausal women because the ovaries produce oestrogen through a completely different pathway that AIs do not block. However, when combined with ovarian function suppression (OFS) — either GnRH agonists like goserelin or leuprolide, or surgical oophorectomy — AIs become highly effective in premenopausal women. The SOFT and TEXT trials demonstrated that OFS + AI provides better disease-free survival than tamoxifen alone in high-risk premenopausal ER+ breast cancer. If your oncologist has prescribed an AI, ensure you are also receiving adequate ovarian suppression.
Is it safe to take vitamin D and calcium supplements with an aromatase inhibitor?
Yes — calcium and vitamin D supplementation is not just safe, it is actively recommended alongside aromatase inhibitors to counteract AI-associated bone loss. The recommended doses are calcium 1,000–1,200 mg/day (from diet and supplements combined) and vitamin D 800–1,000 IU/day. Have your serum 25-OH vitamin D level checked at the start of AI therapy — many patients are vitamin D deficient at baseline, and repleting to >75 nmol/L significantly reduces AI-related arthralgia as well as protecting bone density.
My AI has stopped working — my cancer has progressed. What are the next options?
Progression on an aromatase inhibitor defines endocrine resistance, and the next treatment depends on whether disease is early or metastatic. For metastatic ER+/HER2− breast cancer progressing on an AI: CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with fulvestrant or letrozole are the standard second-line approach — with median progression-free survival of 12–18 months. If PIK3CA mutation is present (in the primary or metastatic biopsy), alpelisib + fulvestrant is an option. For ESR1-mutant disease (common after prior AI), elacestrant (Orserdu) is newly available as an oral SERD. The options for endocrine-resistant ER+ breast cancer have expanded substantially in the last five years.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Managing Aromatase Inhibitor Side Effects?
CancerFax connects patients with specialist breast oncologists who can review your AI side effects, recommend switching strategies, and advise on bone health monitoring — ensuring you complete the full planned duration of endocrine therapy.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.